| 规格: | 98% |
| 分子量: | 451.47 |
| 包装 | 价格(元) |
| 250mg | 电议 |
| 500mg | 电议 |
Background:
CCR1 antagonist 8 (compound 19n), a third azaindazole series compound, is a CCR1 antagonist clinical candidate, with an IC50 of 1.8 nM in Ca2+ flux assay[1].
[1]. Harcken C, et al. Identification of novel azaindazole CCR1 antagonist clinical candidates. Bioorg Med Chem Lett. 2019 Feb 1;29(3):441-448.
m.cnreagent.com